Results 41 to 50 of about 77,046 (263)

Synchronization‐Dissipation in the Cardiorespiratory System

Advanced Science, EarlyView.
By modeling central nervous coupling and viscoelastic interactions in the cardiorespiratory system we show that synchronization produces a 10% gain in cardiac efficiency in humans. It is surmised that respiratory sinus arrhythmia improves cardiac pumping efficiency by reducing dynamic stress and power dissipation in the pulmonary vasculature.
Joshua R. Border, Alain Nogaret, Andrew Lefevre, Vishal Jain   +3 more
wiley   +1 more source

Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma

Biochemistry and Biophysics Reports, 2020
Background: Non Hodgkin lymphoma (NHL) is one of the immune system cancers. The occurrence and progression of malignant lymphomas depends on cellular pathways deregulation. Understanding the relationship between the immune system at the genetic level and
Nesreen G Elhelbawy, Adel A.H. Nassar, Abd ElMonem A Eltorgoman, Safa M Saber, Eman AE Badr   +4 more
doaj   +1 more source

Single‐Cell Profiling Identifies SLC2A5‐Mediated Fructose Metabolism as a Vulnerability in Primary CNS Lymphoma

Advanced Science, EarlyView.
Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu, Qianru Zhang, Wenqiang Yan, Lu Sun, Yiran Cui, Bolin Liu, Guoqing Han, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Qingguo Li, Gang An, Yuxuan Liu   +13 more
wiley   +1 more source

LIMFOMA NON-HODGKIN SEL B PADA MAMMAE

Jurnal Kesehatan Andalas, 2019
Limfoma mammae merupakan kasus yang jarang karena jaringan limfoid tidak ada di regio mammae. Subtipe non-Hodgkin lymphoma (NHL) berkisar 0,5% dari karsinoma mammae, 1% dari semua NHL dan 2% dari limfoma ekstranodal.
Ninda Septia Yuspar, Irza Wahid
doaj   +1 more source

Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma. [PDF]

PLoS ONE, 2015
Indolent B- cell non-Hodgkin lymphoma can transform into aggressive lymphoma. We extend our prior mathematical model to analyze and predict transformation.
Robert F Weiss, Mitchell R Smith, Merlin G Miller, John F Cronin   +3 more
doaj   +1 more source

Genetic alterations in B-cell non-Hodgkin's lymphoma

Vojnosanitetski pregled, 2005
Background. Although the patients with diagnosed B-NHL are classified into the same disease stage on the basis of clinical, histopathological, and immunological parameters, they respond significantly different to the applied treatment. This points out the possibility that within the same group of lymphoma there are different diseases at molecular level.
Zvonko Magic, Tamara Novkovic, Bojana Cikota, Olga Tasic-Radic, Olivera Tarabar, Dragana Stamatovic   +5 more
openaire   +3 more sources

EpCAM+ Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

Advanced Science, EarlyView.
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun, Jinyoung Kim, Chang Gon Kim, Seokhyeong Go, Mina Han, Yujin Ouck, Soojin Jang, Seong Uk Son, Gamin Kim, Wonrak Son, Eunjung Kim, Min Hee Hong, Ja Hyun Yeo, Eun‐Kyung Lim, Hye Ryun Kim, Seungjoo Haam   +15 more
wiley   +1 more source

Primary non-hodgkin′s lymphoma of bone: Experience of a decade

Indian Journal of Pathology and Microbiology, 2010
Objective: To study the prevalence and characterization of primary non Hodgkin′s lymphoma of bone in a major referral center of Pakistan. Methodology: All cases of primary non Hodgkin′s lymphoma of bone, diagnosed at a referral center in ...
Qureshi Asim, Ali Anum, Riaz Nashmia, Pervez Shahid   +3 more
doaj  

The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma

High Yield Medical Reviews
Chimeric Antigen Receptor (CAR) T-cell therapy has improved outcomes in multiple hematological malignancies, such as multiple myeloma and non-Hodgkin lymphoma.
Emaan Haque, Ahmad AlKayyat, Jacqueline Rios, Meera Khosla, Ibrahim Muhsen   +4 more
doaj   +1 more source

Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. [PDF]

PLoS ONE, 2009
A chimeric HLA-DR4-H2-E (DR4) homozygous transgenic mouse line spontaneously develops diverse hematological malignancies with high frequency (70%).
Silke H Raffegerst, Gabriele Hoelzlwimmer, Sandra Kunder, Josef Mysliwietz, Leticia Quintanilla-Martinez, Dolores J Schendel   +5 more
doaj   +1 more source